ViaLase Closes $40M Series Funding Round
ALISA VIEJO, Calif., April 2, 2024 — ViaLase, a clinical-stage medical technology company developing lasers for the treatment of glaucoma, has closed a $40 million series C funding round. Proceeds from the round will be used to continue commercialization of the ViaLase Laser technology including clinical, regulatory, and other commercial milestones. If approved, the ViaLase Laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma, ViaLase said. The ViaLuxe Laser System combines